Last reviewed · How we verify
NCT03588117: PROMIS
Prospective Metabolic Indicator Study
trial testing Physician-supervised nonsurgical weight management program in Metabolic Syndrome in 479 participants. Completed in 30 June 2017.
30 June 2017
Quick facts
| Lead sponsor | Medi-Weightloss Franchising USA, LLC |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 479 |
| Start date | 1 March 2015 |
| Primary completion | 30 June 2017 |
| Estimated completion | 30 June 2017 |
Drugs / interventions tested
- Physician-supervised nonsurgical weight management program
Conditions studied
- Metabolic Syndrome — all drugs for Metabolic Syndrome →
Sponsor
Medi-Weightloss Franchising USA, LLC
Who can join
Adults 19 to 83, any sex, with Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study was to assess the impact of a physician-supervised non-surgical medical weight management program on prevalence of metabolic syndrome and to examine the relationship between program retention and levels of key indicators of metabolic syndrome among participants that self-enrolled to the program. A total of 479 overweight or obese participants aged 19 years or older were observed. The revised National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria were used to define metabolic syndrome.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of an intensive lifestyle intervention on the prevalence of metabolic syndrome and its components among overweight and obese adults.
Guzmán M, Zbella E, Alvarez SS, Nguyen JL, et al · · 2020 · cited 8× · PMID 31840755 · DOI 10.1093/pubmed/fdz170
Verify or expand the search:
- PubMed search for NCT03588117
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Syndrome
Currently open trials in the same condition.
- NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
- NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
- NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03588117 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medi-Weightloss Franchising USA, LLC
- Last refreshed: 17 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03588117.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing